1. Home
  2. UAN vs MGTX Comparison

UAN vs MGTX Comparison

Compare UAN & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CVR Partners LP

UAN

CVR Partners LP

HOLD

Current Price

$127.50

Market Cap

1.1B

Sector

Industrials

ML Signal

HOLD

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

HOLD

Current Price

$11.89

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UAN
MGTX
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2008
2018

Fundamental Metrics

Financial Performance
Metric
UAN
MGTX
Price
$127.50
$11.89
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$24.57
AVG Volume (30 Days)
18.8K
688.1K
Earning Date
04-29-2026
05-12-2026
Dividend Yield
7.91%
N/A
EPS Growth
61.98
33.02
EPS
12.06
N/A
Revenue
$606,038,000.00
$81,391,000.00
Revenue This Year
N/A
$141.38
Revenue Next Year
N/A
N/A
P/E Ratio
$10.60
N/A
Revenue Growth
15.36
144.57
52 Week Low
$86.43
$6.62
52 Week High
$139.50
$15.35

Technical Indicators

Market Signals
Indicator
UAN
MGTX
Relative Strength Index (RSI) 66.91 47.40
Support Level $121.55 $8.84
Resistance Level $139.42 $11.85
Average True Range (ATR) 2.80 0.59
MACD 0.91 -0.19
Stochastic Oscillator 83.90 28.08

Price Performance

Historical Comparison
UAN
MGTX

About UAN CVR Partners LP

CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Share on Social Networks: